Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CG Oncology

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Jan 25, 2024 10:32pm

388 Views

Post# 35846376

RE:RE:RE:RE:RE:RE:RE:CG Oncology

From the very beginning ONC has always made a corporate decision to have small number of patients in their trials. I follow ELVN and they have just announced 2 trials both with an excess of 100 patients. How can you ever say conclusively you have statistical significance with 10 to 15 patients. What's the point.

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch